JP2003531199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003531199A5 JP2003531199A5 JP2001578418A JP2001578418A JP2003531199A5 JP 2003531199 A5 JP2003531199 A5 JP 2003531199A5 JP 2001578418 A JP2001578418 A JP 2001578418A JP 2001578418 A JP2001578418 A JP 2001578418A JP 2003531199 A5 JP2003531199 A5 JP 2003531199A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- conhch
- compound
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC*(C(C(NCC(NC(C(O)=O)C1=CC=CCC1)=C)=O)O)NC(C(*c1cc(CCCCCCCC(N[C@]2C3CCCCC3)=O)ccc1)NC2=O)=O Chemical compound CCC*(C(C(NCC(NC(C(O)=O)C1=CC=CCC1)=C)=O)O)NC(C(*c1cc(CCCCCCCC(N[C@]2C3CCCCC3)=O)ccc1)NC2=O)=O 0.000 description 38
- 125000000217 alkyl group Chemical group 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 26
- -1 aryl-heteroaryl Chemical group 0.000 description 19
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 125000002877 alkyl aryl group Chemical group 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 7
- 125000004404 heteroalkyl group Chemical group 0.000 description 7
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 5
- 235000013877 carbamide Nutrition 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 101710144111 Non-structural protein 3 Proteins 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000113 cyclohexyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000001544 thienyl group Chemical class 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- MTYIELILHRTMRW-QVOQEABFSA-N CC(C(C(NCC(NC(C(O)=O)c1ccccc1)=O)=O)=O)NC(C(CC(CC=C1)C=C1OCCCCCC(C(N[C@H]1C2CCCCC2)=O)=C)NC1=O)=O Chemical compound CC(C(C(NCC(NC(C(O)=O)c1ccccc1)=O)=O)=O)NC(C(CC(CC=C1)C=C1OCCCCCC(C(N[C@H]1C2CCCCC2)=O)=C)NC1=O)=O MTYIELILHRTMRW-QVOQEABFSA-N 0.000 description 1
- BYKYPYPHULOVEW-UHFFFAOYSA-N CC(C)C(CC1)CCC1(F)F Chemical compound CC(C)C(CC1)CCC1(F)F BYKYPYPHULOVEW-UHFFFAOYSA-N 0.000 description 1
- DWPMJTVAEDBIES-UHFFFAOYSA-N CC(CC1)CCN1C(C)=O Chemical compound CC(CC1)CCN1C(C)=O DWPMJTVAEDBIES-UHFFFAOYSA-N 0.000 description 1
- BPNDWFMXDNUGNH-SQIAPHFMSA-N CCCC(C(C(NCC(NC(C(N)=C1CC1)c1ccccc1)O)O)=O)NC(C(CCCCNC(Cc1ccc(CC(N[C@H]2C3CCCCC3)=C)cc1)=O)NC2=O)=O Chemical compound CCCC(C(C(NCC(NC(C(N)=C1CC1)c1ccccc1)O)O)=O)NC(C(CCCCNC(Cc1ccc(CC(N[C@H]2C3CCCCC3)=C)cc1)=O)NC2=O)=O BPNDWFMXDNUGNH-SQIAPHFMSA-N 0.000 description 1
- IBTHWBCNCFKRJY-MHARVHOESA-N CCCC(C(C(NCC(NC(C(N)O)C1=CC=CCC1)=O)O)=O)NC(C(CCCCNC(Cc1ccc(CC(N[C@H]2C3CCCCC3)=O)cc1)=O)NC2=O)=O Chemical compound CCCC(C(C(NCC(NC(C(N)O)C1=CC=CCC1)=O)O)=O)NC(C(CCCCNC(Cc1ccc(CC(N[C@H]2C3CCCCC3)=O)cc1)=O)NC2=O)=O IBTHWBCNCFKRJY-MHARVHOESA-N 0.000 description 1
- XQAJKBOJKGQFQW-RKJAHWQASA-N CCCC(C(C(NCC(NC(C(O)=O)C1=CCCC=C1)=O)=O)=O)NC(C(Cc1cccc(Oc2ccc(CCCCC(CCC[C@H]3C)=O)cc2)c1)NC3=O)=O Chemical compound CCCC(C(C(NCC(NC(C(O)=O)C1=CCCC=C1)=O)=O)=O)NC(C(Cc1cccc(Oc2ccc(CCCCC(CCC[C@H]3C)=O)cc2)c1)NC3=O)=O XQAJKBOJKGQFQW-RKJAHWQASA-N 0.000 description 1
- 101100391182 Dictyostelium discoideum forI gene Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 150000004789 alkyl aryl sulfoxides Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005362 aryl sulfone group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- UZMZVDOOVXLRID-UHFFFAOYSA-N azanylidyne-(nitrosulfonylamino)methane Chemical class [O-][N+](=O)S(=O)(=O)NC#N UZMZVDOOVXLRID-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- NMGFRGWSRHOQOP-UHFFFAOYSA-N carbamic acid;urea Chemical compound NC(N)=O.NC(O)=O NMGFRGWSRHOQOP-UHFFFAOYSA-N 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical compound NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001559 cyclopropyl group Chemical class [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- MGQNMYSRDBFUIR-UHFFFAOYSA-N nitro cyanoformate Chemical compound [O-][N+](=O)OC(=O)C#N MGQNMYSRDBFUIR-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000005936 piperidyl group Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19820400P | 2000-04-19 | 2000-04-19 | |
| US60/198,204 | 2000-04-19 | ||
| PCT/US2001/012530 WO2001081325A2 (en) | 2000-04-19 | 2001-04-17 | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003531199A JP2003531199A (ja) | 2003-10-21 |
| JP2003531199A5 true JP2003531199A5 (enExample) | 2008-02-28 |
| JP4748912B2 JP4748912B2 (ja) | 2011-08-17 |
Family
ID=22732422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001578418A Expired - Fee Related JP4748912B2 (ja) | 2000-04-19 | 2001-04-17 | アルキルおよびアリールアラニンｐ２部分を含むｃ型肝炎ウイルスに対する大員環ｎｓ３−セリンプロテアーゼ阻害剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6914122B2 (enExample) |
| EP (1) | EP1274724A2 (enExample) |
| JP (1) | JP4748912B2 (enExample) |
| KR (1) | KR20020097220A (enExample) |
| CN (3) | CN1935833A (enExample) |
| AR (1) | AR030558A1 (enExample) |
| AU (1) | AU2001253621A1 (enExample) |
| BR (1) | BR0110104A (enExample) |
| CA (1) | CA2406532A1 (enExample) |
| CZ (1) | CZ20023473A3 (enExample) |
| HK (1) | HK1048479A1 (enExample) |
| HU (1) | HUP0302957A2 (enExample) |
| IL (1) | IL151935A0 (enExample) |
| MX (1) | MXPA02010375A (enExample) |
| NO (1) | NO20025030L (enExample) |
| NZ (1) | NZ521456A (enExample) |
| PE (1) | PE20011288A1 (enExample) |
| PL (1) | PL358591A1 (enExample) |
| RU (1) | RU2002131163A (enExample) |
| SK (1) | SK14952002A3 (enExample) |
| WO (1) | WO2001081325A2 (enExample) |
| ZA (1) | ZA200208014B (enExample) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| AU3659102A (en) * | 2000-12-12 | 2002-06-24 | Schering Corp | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
| MXPA03006514A (es) | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
| US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
| US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| EP1497282A2 (en) * | 2002-04-11 | 2005-01-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| CL2004001161A1 (es) | 2003-05-21 | 2005-04-08 | Boehringer Ingelheim Int | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. |
| US20090198050A1 (en) * | 2003-06-18 | 2009-08-06 | Tranzyme Pharma Inc. | Macrocyclic Modulators of the Ghrelin Receptor |
| US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| DE602004025569D1 (de) | 2003-06-18 | 2010-04-01 | Tranzyme Pharma Inc | Makrozyklische motilin rezeptorantagonisten |
| US8921521B2 (en) | 2003-06-18 | 2014-12-30 | Ocera Therapeutics, Inc. | Macrocyclic modulators of the Ghrelin receptor |
| MXPA06002250A (es) | 2003-08-26 | 2006-05-17 | Schering Corp | Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c. |
| MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| EP1673385B1 (en) | 2003-09-22 | 2011-03-02 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
| CN1894274A (zh) | 2003-09-26 | 2007-01-10 | 先灵公司 | 丙肝病毒ns3丝氨酸蛋白酶的大环抑制剂 |
| NZ546663A (en) | 2003-10-10 | 2010-01-29 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
| WO2005043118A2 (en) * | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
| MXPA06005683A (es) | 2003-11-20 | 2006-12-14 | Schering Corp | Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c. |
| WO2005070955A1 (en) | 2004-01-21 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
| EP1711515A2 (en) | 2004-02-04 | 2006-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| CN1950393A (zh) | 2004-02-27 | 2007-04-18 | 先灵公司 | 丙型肝炎病毒ns3蛋白酶的抑制剂 |
| RU2006134002A (ru) | 2004-02-27 | 2008-04-10 | Шеринг Корпорейшн (US) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с |
| RU2428428C9 (ru) | 2004-02-27 | 2012-03-10 | Шеринг Корпорейшн | Серусодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с |
| US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| RU2006134005A (ru) | 2004-02-27 | 2008-04-10 | Шеринг Корпорейшн (US) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с |
| ATE438622T1 (de) | 2004-02-27 | 2009-08-15 | Schering Corp | 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
| CN1984922A (zh) | 2004-05-20 | 2007-06-20 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸 |
| JP4914355B2 (ja) | 2004-07-20 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類似体 |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| MX2007002371A (es) | 2004-08-27 | 2007-04-23 | Schering Corp | Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| WO2007001406A2 (en) * | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| US7772178B2 (en) * | 2005-06-02 | 2010-08-10 | Schering Corporation | Pharmaceutical formulations and methods of treatment using the same |
| US8119602B2 (en) | 2005-06-02 | 2012-02-21 | Schering Corporation | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
| US20110104109A1 (en) * | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
| EP2305696A3 (en) * | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| RU2436787C2 (ru) * | 2005-07-29 | 2011-12-20 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
| ES2401661T3 (es) * | 2005-08-02 | 2013-04-23 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas |
| RU2446171C2 (ru) * | 2005-08-19 | 2012-03-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способы и промежуточные продукты |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| EA200801050A1 (ru) | 2005-10-11 | 2008-12-30 | Интермьюн, Инк. | Соединения и способы ингибирования репликации вирусного гепатита с |
| US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| NZ568324A (en) | 2005-11-11 | 2012-01-12 | Vertex Pharma | Hepatitis C virus variants |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP1991229A2 (en) | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| JP2009531315A (ja) | 2006-03-16 | 2009-09-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 重水素化ｃ型肝炎プロテアーゼインヒビター |
| MX2008012225A (es) * | 2006-03-23 | 2008-12-03 | Schering Corp | Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas. |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
| WO2008019477A1 (en) | 2006-08-17 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| WO2008048121A2 (en) | 2006-10-18 | 2008-04-24 | Lincoln University | Macrocyclic cysteine protease inhibitors and compositions thereof |
| JP5079818B2 (ja) | 2006-12-22 | 2012-11-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体 |
| KR20090106539A (ko) * | 2006-12-22 | 2009-10-09 | 쉐링 코포레이션 | Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체 |
| JP5055377B2 (ja) | 2006-12-22 | 2012-10-24 | シェーリング コーポレイション | ［５，６−環］環形成インドール誘導体およびその使用方法 |
| EA200970806A1 (ru) * | 2007-02-27 | 2010-08-30 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| US8575208B2 (en) * | 2007-02-27 | 2013-11-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| WO2008137779A2 (en) * | 2007-05-03 | 2008-11-13 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| MX2009011930A (es) | 2007-05-04 | 2009-11-18 | Vertex Pharma | Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c. |
| CA2686546A1 (en) * | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| WO2009018657A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| RU2010111550A (ru) * | 2007-08-29 | 2011-10-10 | Шеринг Корпорейшн (US) | 2,3-замещенные индольные производные для лечения вирусных инфекций |
| EP2195317B1 (en) | 2007-08-29 | 2012-01-18 | Schering Corporation | 2,3-substituted azaindole derivatives for treating viral infections |
| WO2009032124A1 (en) * | 2007-08-29 | 2009-03-12 | Schering Corporation | Substituted indole derivatives and methods of use thereof |
| EP2436682A1 (en) * | 2007-08-30 | 2012-04-04 | Vertex Pharmceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| US8765757B2 (en) * | 2007-11-16 | 2014-07-01 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| CN102317285A (zh) * | 2007-11-16 | 2012-01-11 | 先灵公司 | 3-氨基磺酰基取代的吲哚衍生物及其使用方法 |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| US8309685B2 (en) * | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| WO2009082697A1 (en) * | 2007-12-21 | 2009-07-02 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
| CN104557880A (zh) * | 2007-12-21 | 2015-04-29 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| RU2490272C2 (ru) * | 2008-02-04 | 2013-08-20 | Айденикс Фармасьютикалз, Инк. | Макроциклические ингибиторы серинпротеазы |
| CA2705300A1 (fr) * | 2008-02-15 | 2009-06-04 | Xeda International | Macrocyclic inhibitors of hepatitis c protease |
| CA2719008A1 (en) | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors |
| WO2009142842A2 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| JP5580814B2 (ja) * | 2008-06-13 | 2014-08-27 | メルク・シャープ・アンド・ドーム・コーポレーション | ３環式インドール誘導体およびその使用方法 |
| WO2010022121A1 (en) | 2008-08-20 | 2010-02-25 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| WO2010022128A1 (en) | 2008-08-20 | 2010-02-25 | Schering Corporation | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| CA2734487A1 (en) | 2008-08-20 | 2010-02-25 | Southern Research Institute | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| US8470834B2 (en) | 2008-08-20 | 2013-06-25 | Merck Sharp & Dohme Corp. | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| KR20110116136A (ko) | 2009-01-07 | 2011-10-25 | 싸이넥시스, 인크. | Ｈｃｖ 및 ｈｉｖ 감염의 치료에 사용하기 위한 사이클로스포린 유도체 |
| US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| JP2012528195A (ja) | 2009-05-29 | 2012-11-12 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物 |
| AR077712A1 (es) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | Inhibidores de serina proteasa macrociclica |
| EP2470189A4 (en) | 2009-08-27 | 2013-01-23 | Merck Sharp & Dohme | METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS |
| CN105001302A (zh) * | 2009-09-28 | 2015-10-28 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| WO2011066241A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| MY159958A (en) | 2009-12-18 | 2017-02-15 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| WO2011087740A1 (en) | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| US9433621B2 (en) | 2010-02-18 | 2016-09-06 | Merck Sharp & Dohme Corp. | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| MA34147B1 (fr) | 2010-03-09 | 2013-04-03 | Merck Sharp & Dohme | Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales |
| EP2576564A4 (en) | 2010-06-07 | 2014-01-22 | Abbvie Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| CA2805440A1 (en) | 2010-07-26 | 2012-02-09 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| EP2621279B1 (en) | 2010-09-29 | 2018-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途 |
| WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
| EP2489669A1 (en) * | 2011-02-18 | 2012-08-22 | Helmholtz-Zentrum für Infektionsforschung GmbH | Haprolid and derivatives thereof as inhibitors of HCV |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| WO2012142085A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| US20140378416A1 (en) | 2011-09-14 | 2014-12-25 | Michael P. Dwyer | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| TWI852183B (zh) * | 2011-12-28 | 2024-08-11 | 日商中外製藥股份有限公司 | 胜肽化合物之環化方法 |
| EP2943493B1 (en) * | 2013-01-09 | 2017-08-02 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015065817A1 (en) | 2013-10-30 | 2015-05-07 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
| WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| US10815489B2 (en) | 2015-03-13 | 2020-10-27 | Chugai Seiyaku Kabushiki Kaisha | Modified aminoacyl-tRNA synthetase and use thereof |
| WO2018032467A1 (en) | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases |
| WO2018032468A1 (en) | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| US12391971B2 (en) | 2017-01-31 | 2025-08-19 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptides in cell-free translation system |
| EP3636656A4 (en) | 2017-06-09 | 2021-04-14 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF SYNTHESIS OF PEPTIDE WITH N-SUBSTITUTED AMINO ACID |
| US11834515B2 (en) | 2017-10-11 | 2023-12-05 | Cornell University | Macrocyclic compounds as proteasome inhibitors |
| CN111479819B (zh) | 2017-12-15 | 2024-06-14 | 中外制药株式会社 | 制备肽的方法和处理碱的方法 |
| US12312297B2 (en) | 2018-11-07 | 2025-05-27 | Chugai Seiyaku Kabushiki Kaisha | O-substituted serine derivative production method |
| CN119143631A (zh) | 2018-11-30 | 2024-12-17 | 中外制药株式会社 | 用于肽化合物或酰胺化合物的脱保护方法和在固相反应中的树脂脱除方法以及用于生产肽化合物的方法 |
| KR102994657B1 (ko) | 2019-03-15 | 2026-07-22 | 추가이 세이야쿠 가부시키가이샤 | 방향족 아미노산 유도체의 제조 방법 |
| EP4043478A4 (en) | 2019-11-07 | 2024-01-03 | Chugai Seiyaku Kabushiki Kaisha | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION |
| UA130266C2 (uk) * | 2021-04-28 | 2025-12-31 | Ніппон Стіл Корпорейшн | Сталева труба для нафтової свердловини |
| CN121452444B (zh) * | 2025-11-11 | 2026-04-17 | 江西省第九地质勘察规划有限公司 | 用于水文地质勘探中取样的固定装置 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5377083A (en) * | 1976-12-16 | 1978-07-08 | Asahi Chem Ind Co Ltd | Penicillins and their derivatives |
| US4260601A (en) * | 1979-10-23 | 1981-04-07 | Nyegaard & Co. A/S | Chemical compounds |
| FI77875C (fi) * | 1982-11-26 | 1989-05-10 | Nyegaard & Co As | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptider. |
| US4956344A (en) * | 1987-09-17 | 1990-09-11 | Hafslund Nycomed A/S | Method for treatment of lesions in the large intestinal epithelium with a tripeptide |
| WO1989004669A1 (en) | 1987-11-18 | 1989-06-01 | Chiron Corporation | Nanbv diagnostics and vaccines |
| ATE132182T1 (de) | 1989-02-01 | 1996-01-15 | Asahi Glass Co Ltd | Azeotrope oder azeotropähnliche zusammensetzung auf der basis von chlorfluorkohlenwasserstoffen |
| AU7675491A (en) | 1990-04-04 | 1991-10-30 | Chiron Corporation | Hepatitis c virus protease |
| JPH07228594A (ja) * | 1994-02-18 | 1995-08-29 | Suntory Ltd | エンドセリン受容体拮抗ペプチド |
| IL109943A (en) * | 1994-06-08 | 2006-08-01 | Develogen Israel Ltd | Conformationally constrained backbone cyclized peptide analogs |
| WO1998007734A1 (en) | 1996-08-21 | 1998-02-26 | Hybridon, Inc. | Oligonucleotide prodrugs |
| NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| PT1012180E (pt) * | 1997-08-11 | 2005-04-29 | Boehringer Ingelheim Ca Ltd | Analogos de peptidos inibidores da hepatite c |
| JP2002511483A (ja) * | 1998-04-15 | 2002-04-16 | アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド | 樹脂結合環状ペプチドの製造方法 |
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| AR022061A1 (es) * | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6407066B1 (en) * | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
-
2001
- 2001-04-17 AU AU2001253621A patent/AU2001253621A1/en not_active Abandoned
- 2001-04-17 EP EP01927142A patent/EP1274724A2/en not_active Withdrawn
- 2001-04-17 IL IL15193501A patent/IL151935A0/xx unknown
- 2001-04-17 AR ARP010101794A patent/AR030558A1/es unknown
- 2001-04-17 RU RU2002131163/04A patent/RU2002131163A/ru not_active Application Discontinuation
- 2001-04-17 HU HU0302957A patent/HUP0302957A2/hu unknown
- 2001-04-17 CZ CZ20023473A patent/CZ20023473A3/cs unknown
- 2001-04-17 SK SK1495-2002A patent/SK14952002A3/sk not_active Application Discontinuation
- 2001-04-17 WO PCT/US2001/012530 patent/WO2001081325A2/en not_active Ceased
- 2001-04-17 PL PL01358591A patent/PL358591A1/xx not_active Application Discontinuation
- 2001-04-17 PE PE2001000348A patent/PE20011288A1/es not_active Application Discontinuation
- 2001-04-17 CA CA002406532A patent/CA2406532A1/en not_active Abandoned
- 2001-04-17 JP JP2001578418A patent/JP4748912B2/ja not_active Expired - Fee Related
- 2001-04-17 US US09/836,636 patent/US6914122B2/en not_active Expired - Fee Related
- 2001-04-17 BR BR0110104-8A patent/BR0110104A/pt not_active IP Right Cessation
- 2001-04-17 CN CNA2006101537103A patent/CN1935833A/zh active Pending
- 2001-04-17 HK HK03100478.8A patent/HK1048479A1/zh unknown
- 2001-04-17 MX MXPA02010375A patent/MXPA02010375A/es active IP Right Grant
- 2001-04-17 CN CN01810566A patent/CN1432022A/zh active Pending
- 2001-04-17 KR KR1020027013965A patent/KR20020097220A/ko not_active Withdrawn
- 2001-04-17 NZ NZ521456A patent/NZ521456A/en unknown
- 2001-04-17 CN CNA2009100067369A patent/CN101580536A/zh active Pending
-
2002
- 2002-10-04 ZA ZA200208014A patent/ZA200208014B/en unknown
- 2002-10-18 NO NO20025030A patent/NO20025030L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530401A5 (enExample) | ||
| RU2002131163A (ru) | Макроциклические ингибиторы ns3-серинпротезы вируса гепатита с, содержащие алкил- и арилаланиновые p2 фрагменты | |
| JP2004515464A5 (enExample) | ||
| JP2004513881A5 (enExample) | ||
| JP2005515255A5 (enExample) | ||
| CA2405521A1 (en) | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties | |
| JP2004504404A5 (enExample) | ||
| RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| JP2007525514A5 (enExample) | ||
| JP2007525518A5 (enExample) | ||
| JP2007525510A5 (enExample) | ||
| JP2005524628A5 (enExample) | ||
| JP2008509218A5 (enExample) | ||
| CA2410662A1 (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| JP2007525512A5 (enExample) | ||
| JP2005511531A5 (enExample) | ||
| RU2006134002A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2004125279A (ru) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита c | |
| RU2003105221A (ru) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с | |
| JP2007535496A5 (enExample) | ||
| JP2006515858A5 (enExample) | ||
| RU2008128452A (ru) | Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения | |
| IT1228293B (it) | Benzoderivati di composti eterociclici contenenti azoto. | |
| JP2005537248A5 (enExample) | ||
| JP2004527515A5 (enExample) |